Latest Posts
-
Turning Antibody Innovation into Real-World Value
A Pharma Talks Interview with Yo (Max) Amakusa, CEO of iBody 1. The evolution of iBody Jens Kurth: iBody initially focused on therapeutic antibodies before successfully expanding into diagnostic antibodies. What led to this strategic shift, and what opportunities did you see that others perhaps overlooked? Amakusa-san: Initially, our goal was to use our proprietary…
-
Pharma Talks: Science Opens the Door – Execution Creates Value
A Conversation with Dr. Bettina Ernst on Biotech Investing, Company Building and the Future of Innovation 26 August 2026 The Investment Landscape Pharma Talks: The biotech investment environment has changed significantly over the past decade. From your perspective, what are the most important changes in how investors evaluate opportunities today? Dr. Bettina Ernst: “I think…
-
The Verdict
🏛️ Twelve evenings.Twelve discussions.No consensus. Benjamin Franklin considers that a success.Augustus considers it time spent.Socrates considers it a beginning. The wine is gone.The notebooks are full. “What have we learned?” asks Socrates. Sun Tzu answers first.As so often, unexpectedly. “Most people underestimate preparation.” Augustus adds: “And overestimate arguments.” Confucius: “They underestimate relationships.” Machiavelli: “And ignore…